Mackenzie Financial Corp Acquires 1,074 Shares of STERIS plc (NYSE:STE)

Mackenzie Financial Corp grew its holdings in shares of STERIS plc (NYSE:STE) by 12.9% during the fourth quarter, Holdings Channel reports. The firm owned 9,399 shares of the medical equipment provider’s stock after purchasing an additional 1,074 shares during the period. Mackenzie Financial Corp’s holdings in STERIS were worth $1,932,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Avalon Trust Co acquired a new position in STERIS in the 4th quarter valued at $30,000. Human Investing LLC acquired a new position in STERIS in the 4th quarter valued at $31,000. Anfield Capital Management LLC grew its stake in STERIS by 100.0% in the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 91 shares during the last quarter. Manchester Capital Management LLC grew its stake in STERIS by 182.7% in the 4th quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 137 shares during the last quarter. Finally, Brown Brothers Harriman & Co. grew its stake in STERIS by 66.7% in the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 88 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.

Insider Activity at STERIS

In related news, SVP Cary L. Majors sold 12,828 shares of STERIS stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $250.08, for a total transaction of $3,208,026.24. Following the completion of the transaction, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at $2,843,909.76. This trade represents a 53.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.14% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on STE. Stephens reiterated an “overweight” rating and issued a $250.00 target price on shares of STERIS in a research note on Thursday, May 15th. Piper Sandler raised their price target on shares of STERIS from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Citigroup restated an “outperform” rating on shares of STERIS in a research report on Friday, May 16th. Jefferies Financial Group began coverage on shares of STERIS in a research report on Thursday. They issued a “hold” rating and a $263.00 price target on the stock. Finally, Morgan Stanley raised their price target on shares of STERIS from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research report on Monday, May 19th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $263.83.

STERIS Price Performance

Shares of STERIS stock opened at $245.09 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.40 and a current ratio of 2.13. The firm’s 50-day simple moving average is $227.95 and its 200-day simple moving average is $220.77. STERIS plc has a twelve month low of $200.98 and a twelve month high of $252.79. The firm has a market cap of $24.08 billion, a P/E ratio of 52.04 and a beta of 0.96.

STERIS (NYSE:STE) last issued its earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.15. STERIS had a net margin of 8.66% and a return on equity of 13.91%. The business had revenue of $1.48 billion for the quarter, compared to analyst estimates of $1.47 billion. During the same period in the previous year, the business earned $2.58 EPS. The firm’s revenue was up 5.7% on a year-over-year basis. As a group, research analysts expect that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 26th. Investors of record on Tuesday, June 10th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 0.93%. The ex-dividend date of this dividend is Tuesday, June 10th. STERIS’s dividend payout ratio is currently 36.77%.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.